EU approves Novartis' Ilaris for SJIA

|About: Novartis AG (NVS)|By:, SA News Editor

The European Union approves Novartis' (NVS +2.2%) Ilaris for the treatment of
active systemic juvenile idiopathic arthritis in children 2 and up for whom NSAIDs and corticosteroids have proved inadequate.

"The EU approval of Ilaris provides patients suffering from SJIA with a convenient new treatment option offering a favorable benefit-risk profile, administered as a single monthly subcutaneous injection," a Novartis official says. (PR)